|This Slide: #91 of 100|
Slide #91. Johnson & Johnson — Aragon Pharmaceuticals
Johnson & Johnson (NYSE:JNJ)
Aragon Pharmaceuticals Inc., a leader in developing drugs for hormone driven cancers, today announced a definitive agreement with Johnson & Johnson whereby Aragon will be acquired for $650 million in cash up front along with $350 million in contingent development milestone payments that could bring the total transaction value to $1 billion. The acquisition includes Aragon's androgen receptor antagonist program, including its most advanced compound, ARN-509, a second generation androgen receptor signaling inhibitor that is currently being evaluated in a Phase II trial in patients with castration-resistant prostate cancer.
Johnson & Johnson is a holding company. Through its subsidiaries, Co. is engaged in the research and development, manufacture and sale of products in the health care field. Co. has three business segments: Consumer Health, which includes products focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women's health and wound care markets; Pharmaceutical, which is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension; and Medical Devices, which includes products used in the Interventional Solutions, Orthopaedics, Surgery, and Vision fields.
Johnson and Johnson SEC Filing Email Alerts Service
Open the JNJ Page at The Online Investor »
Free JNJ Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Buy (3.00 out of 4)